BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.

被引：0
作者：
Kim, D.
Saglio, G.
Martinelli, G.
Shou, Y.
Stein, A. M.
Woodman, R. C.
Kantarjian, H.
Hughes, T. P.
Radich, J. P.
Hochhaus, A.
机构：
[1] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[2] Univ Turin, San Luigi Gonzaga Hosp, Orbassano, Italy
[3] Inst Hematol, Bologna, Italy
[4] Novartis Inst BioMed Res, Cambridge, MA USA
[5] Novartis Pharmaceut, Cambridge, MA USA
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] SA Pathol, Dept Haematol, Adelaide, SA, Australia
[9] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[10] Univ Klinikum Jena, Jena, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.6567
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6567
引用
收藏
页数：1
相关论文
共 50 条
[21]   NILOTINIB IS ACTIVE IN IMATINIB RESISTANT AND INTOLERANT CHRONIC MYELOID LEUKEMIA (CML) PATIENTS [J].
Koren-Michowitz, M. K. M. ;
Le Coutre, P. ;
Duyster, J. ;
Scheid, C. ;
Rowe, J. M. ;
Goldschmidt, N. ;
Ribakovsky, E. ;
Nagler, A. .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 :222-223
[22]   Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis [J].
Hiwase, Devendra K. ;
Yeung, David T. ;
Carne, Lisa ;
Ross, David ;
Grigg, Andrew ;
Hughes, Timothy P. .
BLOOD, 2013, 122 (21)
[23]   Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) [J].
Branford, Susan ;
Kim, Dong-Wook ;
Soverini, Simona ;
Gottardi, Enrico ;
Beppu, Lan ;
Mueller, Martin C. ;
Haque, Ariful ;
Shou, Yaping ;
Woodman, Richard C. ;
Kantarjian, Hagop M. ;
Martinelli, Giovanni ;
Radich, Jerald P. ;
Saglio, Giuseppe ;
Hughes, Timothy P. ;
Hochhaus, Andreas .
BLOOD, 2009, 114 (22) :1275-1276
[24]   Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) [J].
Sasaki, Koji ;
Kantarjian, Hagop M. ;
O'Brien, Susan ;
Ravandi, Farhad ;
Konopleva, Marina ;
Borthakur, Gautam ;
Garcia-Manero, Guillermo ;
Wierda, William G. ;
Daver, Naval ;
Ferrajoli, Alessandra ;
Takahashi, Koichi ;
Jain, Preetesh ;
Rios, Mary Beth ;
Pierce, Sherry ;
Jabbour, Elias J. ;
Cortes, Jorge E. .
BLOOD, 2016, 128 (22)
[25]   The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up [J].
Saglio, G. ;
Kantarjian, H. ;
Reiffers, J. ;
Jootar, S. ;
Kalaycio, M. E. ;
Shibayama, H. ;
Fan, X. ;
Gallagher, N. J. ;
Shou, Y. ;
Larson, R. A. ;
Hughes, T. P. ;
Hochhaus, A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[26]   Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations [J].
Mueller, Martin C. ;
Cortes, Jorge ;
Kim, Dong-Wook ;
Druker, Brian J. ;
Erben, Philipp ;
Pasquini, Ricardo ;
Hughes, Timothy P. ;
Matloub, Yousif ;
Ploughman, Lynn ;
Hochhaus, Andreas .
BLOOD, 2008, 112 (11) :171-172
[27]   Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib [J].
Barbosa Pagnano, Katia Borgia ;
Miranda, Eliana Cristina ;
Delamain, Marcia Torresan ;
Duarte, Gislaine Oliveira ;
de Paula, Erich Vinicius ;
Lorand-Metze, Irene ;
de Souza, Carmino Antonio .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (11) :728-733
[28]   Five-year follow-up of patients with imatinib-resistant or - intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib [J].
Shah, N. P. ;
Cortes, J. E. ;
Schiffer, C. A. ;
Guilhot, F. ;
Brummendorf, T. H. ;
Chen, A. C. ;
Healey, D. ;
Lambert, A. ;
Saglio, G. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[29]   Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. [J].
Shah, Neil P. ;
Kantarjian, Hagop ;
Kim, Dong-Wook ;
Hochhaus, Andreas ;
Saglio, Giuseppe ;
Guilhot, Francois ;
Schiffer, Charles Alan ;
Steegmann, Juan Luis ;
Mohamed, Hesham ;
Dejardin, David ;
Healey, Diane I. ;
Cortes, Jorge E. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[30]   Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP) [J].
Jabbour, Elias ;
Kantarjian, Hagop M. ;
Baccarani, Michele ;
de Coutre, Philipp D. ;
Haque, Ariful ;
Gallagher, Neil J. ;
Cortes, Jorge ;
Giles, Francis .
BLOOD, 2008, 112 (11) :1103-1103
12345